Has Karl Staser, MD received payments from drug or device companies?

Yes. Drug and device makers reported $8,777 in general payments to Karl Staser, MD across 278 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Karl Staser, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Karl Staser, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Karl Staser, MD

Dermatology · Evansville, INNPI 1992144174

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,379 of the $8,777 with a category attached, or 72.7%. 25 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 31.1% of the total. Reporting peaked in 2024 at $4,538 and has fallen 79.8% since, to $916 in 2025.

$8,777in general payments, 2019–2025

Across 278 payments — averaging $31.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$3K
AbbVie$2K
Regeneron Healthcare Solutions, Inc.$491
Dermavant Sciences, Inc.$443
Organogenesis Inc.$440
Amgen$394
plus $3K from 19 others

$1,764in research payments, 2019–2025

Across 1 payment — averaging $1764.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Incyte Corporation$2K

What the payments were for

Consulting fees$2,25826%
Food & beverage$6,37973%
Education$1412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	23	$2,727
AbbVie	114	$1,712
Regeneron Healthcare Solutions, Inc.	13	$491
Dermavant Sciences, Inc.	20	$443
Organogenesis Inc.	6	$440
Amgen	5	$394
Novartis	17	$341
Johnson & Johnson	6	$289
LEO Pharma Inc.	14	$283
Sanofi	13	$282
Pfizer	13	$249
Boehringer Ingelheim	2	$232
UCB, Inc.	5	$214
Lilly USA, LLC	10	$184
Kerecis Limited	1	$126
Sun Pharmaceutical Industries Inc.	1	$87
Galderma Laboratories, L.p.	5	$78
Ortho Dermatologics, A Division Of Bausch Health US, LLC	1	$77
Incyte Corporation	2	$39
Genentech USA, Inc.	1	$22
Fresenius Kabi USA, LLC	1	$21
Prugen, Inc. Pharmaceuticals	1	$15
Arcutis Biotherapeutics, Inc.	1	$14
Almirall LLC	1	$12
Organon	2	$7

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,777 in reported general payments places this provider in the 70th percentile of 202 dermatology providers in Indiana.

See all dermatology providers in Indiana →

Medicare billing

Part B allowed, 2024

$231,972

Medicare patients

690

Services billed

4,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Skyrizi PenRisankizumab-Rzaa	22	$478,364
Dupixent PenDupilumab	51	$213,600
Clobetasol Propionate	326	$11,049
Fluorouracil	166	$11,001
Ketoconazole	406	$7,244
Doxycycline Monohydrate	157	$4,304
Metronidazole	67	$3,273
Triamcinolone Acetonide	160	$2,971
Pimecrolimus	20	$2,613
Clindamycin Phosphate	62	$2,585
ValacyclovirValacyclovir Hcl	38	$2,562
Tacrolimus	21	$2,322
Hydrocortisone	143	$1,847
Halobetasol Propionate	29	$1,457
Ciclopirox	37	$1,022

Paid to pharmacies, not to this prescriber.

Other dermatology in Evansville

Charles HudsonEvansville$92K
Thomas SelbyEvansville$15K
Celine MestelEvansville$11K
Jamie MullEvansville$10K
Dylan GreeneyEvansville$8K
Scott GuenthnerPlainfield$1.6M
David RosmarinIndianapolis$1.1M
Christopher ObeimeIndianapolis$907K
Scott FretzinIndianapolis$794K
Priya YoungIndianapolis$492K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →